CAPLaboratoryImprovementPrograms
GeneticHeterogeneityinHER2TestinginBreastCancer
PanelSummaryandGuidelines
GailH.Vance,MD;ToddS.Barry,MD,PhD;KennethJ.Bloom,MD;PatrickL.Fitzgibbons,MD;DavidG.Hicks,MD;
RobertB.Jenkins,MD,PhD;DianeL.Persons,MD;RaymondR.Tubbs,DO;M.ElizabethH.Hammond,MD
●Context.—IntratumoralheterogeneityofHER2geneam-pli cationhasbeenwelldocumentedandrepresentssub-clonaldiversitywithinthetumor.ThereportedincidenceofintratumorHER2ampli cationgeneticheterogeneityrangesintheliteraturefromapproximately5%to30%.ThepresenceofHER2geneticheterogeneitymayincreasesubjectivityinHER2interpretationbythepathologist.Objectives.—Tode neHER2geneticheterogeneityandtoprovidepracticeguidelinesforexaminingandreportingbreasttumorswithgeneticheterogeneityforimprovementofHER2testinginbreastcancer.Design.—WeconvenedanexpertpaneltodiscussHER2geneampli cationtestingby uorescenceinsituhybrid-ization.Componentsaddressedincludedade nitionof
n2007,theAmericanSocietyofClinicalOncologyandtheCollegeofAmericanPathologists(CAP)publishedguidelinesforHER2testinginbreastcancertoimproveaccuracyandreproducibilityofthetestingintheUnitedStates.1,2Atthattime,itwasclearthatasubpopulationofbreastcancersexaminedforHER2geneampli cationby uorescenceinsituhybridization(FISH)displayedintra-tumoralheterogeneity.Itwasalsoclearthatsuchcasescouldgiverisetodiscrepantresultsbetweenimmunohis-tochemistryandFISHassaysforHER2.3TheCAPagreedtoconveneanexpertpaneltoaddressthisissueandpub-lishseparaterecommendations.TheCAPpanelconsistedofpathologistswithspecialexpertiseinbreastcancer,cy-togenetics,clinicalpathology,molecularpathology,imageanalysis,andimmunohistochemistry.Membersofthe
AcceptedforpublicationDecember1,2008.FromtheDepartmentofMedicalandMolecularGenetics,IndianaUniversitySchoolofMedicine,Indianapolis(DrVance);PhenopathLaboratories,Seattle,Washington(DrBarry);theLaboratoryDepart-ment,ClarientDiagnosticServices,AlisoViejo,California(DrBloom);theDepartmentofPathology,StJudeMedicalCenter,Fullerton,Cali-fornia(DrFitzgibbons);theDepartmentofPathology,RoswellParkCan-cerInstitute,Rochester,NewYork(DrHicks);theDepartmentofPa-thology,MayoClinic,Rochester,Minnesota(DrJenkins);theDepart-mentofPathology,UniversityofKansasMedicalCenter,KansasCity(DrPersons);theDepartmentofPathology,ClevelandClinicFounda-tion,Cleveland,Ohio(DrTubbs);andtheDepartmentofPathology,LDSHospital,SaltLakeCity,Utah(DrHammond).Theauthorshavenorelevant nancialinterestintheproductsorcompaniesdescribedinthisarticle.Reprints:GailH.Vance,MD,IndianaUniversitySchoolofMedicine,DepartmentofMedicalandMolecularGenetics,975WestWalnutSt,Rm264,Indianapolis,IN46202(e-mail:ghvance@iupui.edu).
ArchPatholLabMed—Vol133,April2009HER2ampli cationheterogeneity,practiceguidelinesforexaminationofthetissue,andreportingcriteriaforthisanalysis.Results.—Geneticheterogeneityforampli cationofHER2genestatusininvasivebreastcancerisde nedandguidelinesestablishedforassessingandreportingHER2re-sultsinthesecases.Theseguidelinesareadditivetoandexpandthosepublishedin2007bytheAmericanSocietyofClinicalOncologyandtheCollegeofAmericanPathol-ogists.Conclusion.—Standardizedmethodsforanalysiswillim-provetheaccuracyandconsistencyofinterpretationofHER2geneampli cationstatusinbreastcancer.(ArchPatholLabMed.2009;133:611–612)panelincludedindividualsfromlargelaboratorieswithextensiveexperienceinHER2FISHtestingforbreastcan-cer.Theseguidelineswerecreatedin2008duringagroupmeetingheldviaconferencecallandvettedthroughtheCAP/AmericanCollegeofMedicalGeneticsCytogeneticsResourceCommittee.The nalrecommendationswerere-viewedandapprovedbytheentiregroup.DEFINITIONHER2geneticheterogeneity(GH)existsiftherearemorethan5%butlessthan50%ofin ltratingtumorcellswitharatiohigherthan2.2.Forexample,if20cellsarecountedandatleastonecellisidenti edwithaHER2/CEP17signalratiohigherthan2.2,thisspecimencontainsGH.Likewise,if60cellsareexaminedand3ormorecellshavearatiohigherthan2.2,HER2GHispresent.Thisde nitionisbasedonpublishedworkthatdoesnotin-cludeoutcomeanalysisofpatientsbutappearstoberea-sonabletoallcommitteemembers.4–8Ifmorethan50%ofthein ltratingtumorcellshavearatiohigherthan2.2,thenthetumorisconsideredHER2ampli ed.ForFISHmethodologiesusingaprobeforHER2onlywithoutacontrolprobe,HER2GHexistsifthereare 5%but 50%ofin ltratingtumorcellswith 6HER2signalspercell.Insuchcases,practiceguidelinesandreportingcriteriashouldbeusedthatarecomparabletothosede-scribedintheseguidelinesforassaysusingHER2ratios.METHODOFEXAMINATIONTODETERMINEWHETHERGHISPRESENTAhematoxylin-eosin–stainedslidemust rstbeexam-inedbyapathologisttode neregionsofinvasivetumor.GeneticHeterogeneityinHER2Testing—Vanceetal611I
中异质性研究, 包括 Meta 分析中异质性的定义, 并将异质性分为临床异质性、 ...Key words Meta-analysis; Heterogeneity; Classification; Testing methods; ...
中异质性研究, 包括 Meta 分析中异质性的定义, 并将异质性分为临床异质性、 ...Key words Meta-analysis; Heterogeneity; Classification; Testing methods; ...
Meta分析中异质性的 识别与处理毛 智 2013年06月16日 Heterogeneity dentifing 如何识别?怎样处理? 与GRADE ealing rade 目录 hat hat 当我们研究”髋部骨折”的...
? 2013-8-3 Inequality and Heterogeneity 23 (一)核心概念及其含义 ? ? ? 3、异质性(1)概念与测量 根据类别参数和等级参数可以将社会分化的分为两种形式,即...
Meta 分析中异质性的识别与处理魏丽娟 ,董惠娟 The identif ication and solution of heterogeneity in Meta2analysis ( 第二军医大学研究生管理大队 ,上海 200433)...
藏绵羊mtDNA D-loop区的长度异质性研究_生物学_自然科学_专业资料。藏绵羊 mtDNA D-loop 区的长度异质性研究 摘要:用PCR技术扩增藏绵羊线粒体DNA(mtDNA)控制区时...
异质性、经济增长与收入不平等李宾 (北京大学中国经济研究中心) 金一 (美国...Heterogeneity, Economic Growth and Income Inequality Li, Bin (China Center ...
中异质性研究, 包括 Meta 分析中异质性的定义, 并将异质性分为临床异质性、 ...Key words Meta-analysis; Heterogeneity; Classification; Testing methods; ...
中异质性研究, 包括 Meta 分析中异质性的定义, 并将异质性分为临床异质性、 ...Key words Meta-analysis; Heterogeneity; Classification; Testing methods; ...
介绍 Meta 分析中异质性研究, 包括 Meta 分析中异质性的定义, 并将异质性分...Key words? Meta-analysis; Heterogeneity; Classification; Testing methods; ...
热门文档